SciSparc Ltd. (NASDAQ:SPRC – Get Free Report) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 273,800 shares, an increase of 691.3% from the August 31st total of 34,600 shares. Based on an average daily trading volume, of 3,610,000 shares, the short-interest ratio is currently 0.1 days. Approximately 11.2% of the company’s stock are sold short.
SciSparc Trading Down 2.0 %
Shares of SciSparc stock traded down $0.01 during trading hours on Wednesday, hitting $0.25. The company had a trading volume of 261,813 shares, compared to its average volume of 1,761,522. The company’s 50-day moving average is $0.39 and its two-hundred day moving average is $1.00. SciSparc has a twelve month low of $0.24 and a twelve month high of $14.22.
Institutional Trading of SciSparc
A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC purchased a new stake in SciSparc Ltd. (NASDAQ:SPRC – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is owned by institutional investors.
SciSparc Company Profile
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Read More
- Five stocks we like better than SciSparc
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Analyst Think There’s Still Time to Get in on Edgewise, Up 332%
- How to Invest in Small Cap StocksĀ
- 3 Stocks Raising Dividends 4X Higher Than Inflation
- Using the MarketBeat Dividend Yield Calculator
- Palantir Stock Joins the S&P 500; Is It Time to Buy?
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.